title: Poor-risk cytogenetics may be associated with inferior outcome after fludarabine, cytarabine, and amsacrine reduced intensity conditioning in patients with high-risk acute myeloid leukemia.
authors.forename: Christian
authors.initials: C
authors.lastname: Wilhelm
authors.forename: Andreas
authors.initials: A
authors.lastname: Neubauer
authors.forename: Andreas
authors.initials: A
authors.lastname: Burchert
mesh_terms: D000328:Adult; D000677:Amsacrine / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000627:therapeutic use; D003582:Cytogenetics; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D012306:Risk; D019172:Transplantation Conditioning; D016896:Treatment Outcome; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000677:Amsacrine; D003561:Cytarabine; D014740:Vidarabine; C024352:fludarabine